Visilizumab
| Visilizumab | |
|---|---|
| Term | Visilizumab |
| Short definition | Visilizumab - (pronounced) (vih-sih-LIZ-yoo-mab) substance being studied to treat an immune system reaction called graft-versus-host disease (GVHD) that can occur after a donor stem cell transplant. It is also being studied in the treatment of some autoimmune diseases. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Visilizumab - (pronounced) (vih-sih-LIZ-yoo-mab) substance being studied to treat an immune system reaction called graft-versus-host disease (GVHD) that can occur after a donor stem cell transplant. It is also being studied in the treatment of some autoimmune diseases. Visilizumab attaches to a protein called CD3, which is found on some T cells (a type of white blood cell). This can help suppress the body's immune response. Visilizumab is a type of monoclonal antibody
External links
- Medical encyclopedia article on Visilizumab
- Wikipedia's article - Visilizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski